Name (Synonyms) | Correlation | |
---|---|---|
drug234 | Atazanavir Wiki | 1.00 |
drug1831 | Placebo Daclatasvir Wiki | 1.00 |
drug2283 | Sofusbuvir + Daclastavir Wiki | 1.00 |
drug1829 | Placebo Atazanavir Wiki | 1.00 |
drug709 | Daclatasvir Wiki | 0.71 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent that would decrease the peak viral load and, consequently, the associated degree of immunopathological damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among patients under treatment for these aforementioned viruses is empirical less common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that patients with COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir.
Description: Change in area under the SARS-COV 2 viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (isolated antiviral).
Measure: Phase II first step: Change in area under the curve of SARS-COV 2 viral load Time: days 3, 6 and 9 after randomizationDescription: Change in area under the SARS-COV 2 viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (combined antiviral).
Measure: Phase II second step: Change in area under the curve of SARS-COV 2 viral load Time: days 3, 6 and 9 after randomizationDescription: Number of days without oxygen, non-invasive ventilation/high flow nasal cannula or need for mechanical ventilation in 15 days.
Measure: Phase III: Number of free days from respiratory support Time: 15 days